Think the stock market is overpriced or maybe even in a bubble? Think again, say analysts at Barclays.
In the note, entitled Uncomfortably Bullish, they argued that global equity valuations remain in line with longer term averages and below the previous cycle peak, while the outlook for global earnings per share remain the best in nearly five years. Compared with other pricey assets, equities remain the cleanest dirty shirt available to investors, they argue in one chart (see below).
money investment: Express-1 Expedited Solutions Inc.(XPO)
Advisors’ Opinion:
- [By WWW.THESTREET.COM]
In the Lightning Round, Cramer was bullish on GlaxoSmithKline (GSK) , Chubb (CB) , XPO Logistics (XPO) , FedEx (FDX) and Nordson (NDSN) .
Cramer was bearish on Prudential (PRU) , Advanced Semiconductor Engineering (ASX) and ZTO Express (ZTO) .
- [By WWW.THESTREET.COM]
With a trailing 12-month price-to-earnings ratio of 28.79, FedEx’s valuation is in line with UPS (27.52) and far cheaper than XPO Logistics (XPO) (90.25).
money investment: Neogen Corporation(NEOG)
Advisors’ Opinion:
- [By Lisa Levin] Related LOV Match Group And Spark Networks: A Valentine's Day Case Study 20 Biggest Mid-Day Losers For Thursday
Related VKTX 15 Biggest Mid-Day Losers For Tuesday 18 Biggest Mid-Day Losers For Wednesday Companies Reporting Before The Bell
Canadian Solar Inc. (NASDAQ: CSIQ) is expected to report its quarterly earnings at $0.32 per share on revenue of $690.27 million.
General Mills, Inc. (NYSE: GIS) is projected to report its quarterly earnings at $0.71 per share on revenue of $3.84 billion.
Coca-Cola European Partners Plc (NYSE: CCE) is estimated to report its quarterly earnings at $0.45 per share on revenue of $2.72 billion.
Lands' End, Inc. (NASDAQ: LE) is expected to report its quarterly earnings at $0.35 per share on revenue of $459.43 million.
Francesca's Holdings Corp (NASDAQ: FRAN) is estimated to report its quarterly earnings at $0.37 per share on revenue of $145.91 million.
Cheetah Mobile Inc (ADR) (NYSE: CMCM) is projected to report its quarterly earnings at $0.06 per share on revenue of $178.04 million.
Neogen Corporation (NASDAQ: NEOG) is estimated to report its quarterly earnings at $0.27 per share on revenue of $90.05 million.
Lennar Corporation (NYSE: LEN) is projected to post earnings for its first quarter.
Fifth Street Asset Management Inc (NASDAQ: FSAM) is expected to report its quarterly earnings at $0.14 per share on revenue of $25.12 million.
money investment: Prima BioMed Ltd(PBMD)
Advisors’ Opinion:
- [By Monica Gerson]
Prima Biomed (NASDAQ: PBMD) shares dipped 38.59% to touch a new 52-week low of $1.44 after the company reported top-line analysis of CVac Phase 2 trial.
- [By Monica Gerson]
Prima Biomed (NASDAQ: PBMD) dropped 38.17% to $1.45 after the company reported top-line analysis of CVac Phase 2 trial.
Tower Group International (NASDAQ: TWGP) plummeted 24.31% to $10.49. Tower Group announced its plans to release its Q2 results during the week of October 7, 2013. FBR Capital downgraded the stock from Outperform to Market Perform.
money investment: Amgen Inc.(AMGN)
Advisors’ Opinion:
- [By Maxx Chatsko]
Shares of Radius Health (NASDAQ:RDUS) rose over 20% Monday morning after Amgen (NASDAQ:AMGN) announced worrisome complications were discovered during a phase 3 trial for its osteoporosis drug candidate, Evenity. While the drug candidate met its primary endpoint in a more than 4,000-patient phase 3 study, a high rate of serious heart-related side effects were discovered. The drug was previously expected to gain marketing approval from the U.S. Food and Drug Administration in July, but that decision will now be delayed by up to a year or more, if the drug is approved at all.
- [By WWW.THESTREET.COM]
That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.
- [By Ben Levisohn]
What do I mean? Regeneron’s dropped 14% during the last three months, the result of a patent suit with Amgen(AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldn’t be able to sell in the U.S.Then last night, there was finally good news: Ajudge ordered a stay, which would allow Regeneron to sell Praluent, and resulted in a 2% pop in its shares last night after the market close. But then Regeneron reported earnings, and while profits of $3.04 cents a share metthe Street consensus, Regeneron missed on sales and offered disappointing guidance. That caused Regeneron shares to sink 2.1% in pre-open trading.
- [By Keith Speights]
Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY), and Amgen (NASDAQ:AMGN) stand out as three of the most likely suitors for Incyte. Here’s why these big drugmakers could be interested in making a significant acquisition.
